BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng L, Zhang S, Wang M, Lopez-Beltran A. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol 2022:S0046-8177(22)00150-2. [PMID: 35700749 DOI: 10.1016/j.humpath.2022.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Li S, Xia C, Xu D. TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance. Front Immunol 2022;13:1071390. [PMID: 36713366 DOI: 10.3389/fimmu.2022.1071390] [Reference Citation Analysis]
2 Gupta S, Cheng L, Erickson LA. Contemporary Updates in Urologic Pathology: A Special Issue of Renal, Urinary Tract, Prostate, Penile & Testicular Pathology. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.10.001] [Reference Citation Analysis]
3 Walker JM, O’malley P, He M. Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer. Pharmaceutics 2022;14:2027. [DOI: 10.3390/pharmaceutics14102027] [Reference Citation Analysis]
4 Mohanty SK, Lobo A, Cheng L. The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol 2022:S0046-8177(22)00224-6. [PMID: 36084769 DOI: 10.1016/j.humpath.2022.08.006] [Reference Citation Analysis]